Intuitive Surgical, founded in 1995 in Sunnyvale, California, is a pioneering company in the field of minimally invasive robotic-assisted surgery. Its mission is to empower physicians and hospitals to perform less invasive surgeries, improving patient outcomes and healthcare efficiency worldwide[1][5][6]. The company was cofounded by Dr. Frederick H. Moll and Robert Younge, who developed early robotic surgical systems based on telepresence technology pioneered at SRI[2][3]. Intuitive’s flagship product is the da Vinci Surgical System, first launched in 2000, which revolutionized surgery by enabling precise, robot-assisted procedures through small incisions. The da Vinci system rapidly gained adoption in various specialties, including urology, gynecology, thoracic, and general surgery, becoming the most successful robotic surgery platform globally[1][2][3]. By 2019, over 1.2 million procedures had been performed using da Vinci systems, reflecting its widespread clinical impact[3]. Over its history, Intuitive has released five generations of the da Vinci system, with continuous innovations in technology and surgical capabilities. Notably, it expanded its product line with the Ion endoluminal system in 2019, designed for robotic-assisted bronchoscopy and access to peripheral lung tumors[4][6]. In 2024 and 2025, Intuitive launched the da Vinci Single-Port system in Europe and the da Vinci 5 system, respectively, pushing the boundaries of minimally invasive surgery with enhanced precision and access[1]. Intuitive Surgical has grown into a global leader with a market capitalization reaching approximately $70 billion, reflecting its transformative role in healthcare technology and strong financial performance since its IPO in 2000[3]. Its innovations have not only advanced surgical care but also contributed to improved patient recovery, reduced hospital stays, and expanded access to quality surgical treatments worldwide[1][6]. Today, Intuitive continues to invest in digital intelligence, roboti